3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
309
Carcinoma, Non-Small-Cell Lung
281
Prostatic Neoplasms
160
Colorectal Neoplasms
155
Carcinoma, Hepatocellular
144
Neoplasms
134
Leukemia, Myeloid, Acute
132
Lung Neoplasms
115
Squamous Cell Carcinoma of Head and Neck
108
Multiple Myeloma
103
Triple Negative Breast Neoplasms
102
Recurrence
99
Pancreatic Neoplasms
93
Stomach Neoplasms
92
Ovarian Neoplasms
87
Neoplasm Metastasis
87
Lymphoma, Large B-Cell, Diffuse
81
Sarcoma
70
Precursor Cell Lymphoblastic Leukemia-Lymphoma
67
Esophageal Neoplasms
67
Uterine Cervical Neoplasms
66
Melanoma
65
Brain Neoplasms
65
Rectal Neoplasms
62
Head and Neck Neoplasms
62
Glioblastoma
60
Carcinoma, Renal Cell
57
Myelodysplastic Syndromes
55
Lymphoma
55
Esophageal Squamous Cell Carcinoma
54
Interventions
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
HER2-positive Metastatic Breast Cancer
×
Clear all
NCT06595563
2026-05-07
ZEPHIR-02
Jules Bordet Institute
Phase 2
Recruiting
87 enrolled